参附注射液辅助治疗急性重型颅脑损伤患者的效果

Effects of Shenfu injection in adjuvant treatment of acute severe craniocerebral injuries

目的:观察参附注射液辅助治疗急性重型颅脑损伤患者的效果。方法:回顾性分析2016年5月至2018年5月84例急性重型颅脑损伤患者的临床资料,按照治疗方式不同分为对照组和观察组各42例。对照组给予基础治疗,观察组在对照组基础上采用参附注射液治疗,比较两组预后、治疗前后血清神经元特异性烯醇化酶(NSE)水平、血清S100-β蛋白水平、格拉斯哥昏迷指数(GCS)评分和不良反应发生率。结果:观察组预后优于对照组,差异有统计学意义(P<0.05);治疗后,观察组血清NSE水平和S100-β蛋白水平均低于对照组,差异有统计学意义(P<0.05);治疗7、14、28 d后,观察组GCS评分均高于对照组,差异有统计学意义(P<0.05);两组治疗期间均未见明显不良反应。结论:在基础治疗基础上采用参附注射液治疗急性重型颅脑损伤患者可改善预后,降低血清NSE水平和S100-β蛋白水平,效果优于单纯基础治疗。

Objective:To observe effects of Shenfu injection in adjuvant treatment of acute severe craniocerebral injuries.Methods:The clinical data of 84 patients with acute severe craniocerebral injuries from May 2016 to May 2018 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,each with 42 cases.The control group was given basic treatment,while the observation group was treated with Shenfu injection on the basis of that of the control group.The prognosis,the serum neuron-specific enolase(NSE)level,the serum S100-βprotein level,the Glasgow coma index(GCS)score and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The prognosis of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the serum NSE level and the S100-βprotein level of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).After 7,14,and 28 days of treatment,the GCS scores of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).However,there were no obvious adverse reactions during the treatment period in the two groups.Conclusions:On the basis of the basic treatment,Shenfu injection for the patients with acute severe craniocerebral injuries can improve the prognosis and reduce the serum NSE level and S100-βprotein level.Moreover,it is superior to single basic treatment.